FDA Rescinds Zofran ODT ANDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
A prior court decision that Par's ondansetron infringes an unexpired GSK patent prompts FDA to revoke approval.
You may also be interested in...
Hana Biosciences Prepares To Submit First Ondansetron Oral Spray
Pivotal trials confirm Zensana spray is bioequivalent to Zofran tablets for chemotherapy induced nausea and vomiting.
Hana Biosciences Prepares To Submit First Ondansetron Oral Spray
Pivotal trials confirm Zensana spray is bioequivalent to Zofran tablets for chemotherapy induced nausea and vomiting.
Par Acquisition Of Kali Will Help Boost Product Offerings 50% In Two Years
Par will pay $135 mil. for the New Jersey-based generic drug firm. The combined company will have 37 pending ANDAs, including first-to-file application for generic version of J&J's Ultracet.